Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice

American Journal of Pathology

Volumn 166, Issue 6, 2005, Pages 1629-1636

  Chin, Masami ^a   Isono, Motohide ^a   Isshiki, Keiji ^a   Araki, Shin Ichi ^a   Sugimoto, Toshiro ^a   Guo, Baoliang ^a   Sato, Haruhisa ^b   Haneda, Masakazu ^c   Kashiwagi, Atsunori ^a   Koya, Daisuke ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Marutamachi Hospital   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; FIBRONECTIN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HYPERGLYCEMIA; IN VITRO STUDY; KIDNEY INJURY; MESANGIUM CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 21144447745     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62473-X     Document Type: Article

References (36)

1. Neugarten J, Acharya A, Silbiger SR: Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000, 11:319-329
2. U. S. Renal Data System: USRDS 2000 Annual Data Report. NIDDK, The National Institutes of Health, Bethesda, MD, 2000
3. Ballard DJ, Humphrey LL, Melton LJ, Frohnert PP, Chu PC, O'Fallon WM, Palumbo PJ: Epidemiology of persistent proteinuria in type II diabetes mellitus: population-based study in Rochester, Minnesota. Diabetes 1998, 37:405-412
4. Gross ML, Adamczak M, Rabe T, Harbi NA, Krtil J, Koch A, Hamar P, Amann K, Ritz E: Beneficial effects of estrogens on indices of renal damage in uninephrectomized SHRsp rats. J Am Soc Nephrol 2004, 15:348-358
5. Marie C, Sandberg K, Hinojosa-Laborde C: Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol 2004, 15:1546-1556
6. Kwan G, Neugarten J, Sharman M, Ding Q, Fotadar U, Lei J, Silbiger S: Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney Int 1996, 50:1173-1179
7. Silbiger S, Lei J, Ziyadeh FN, Neugarten J: Estradiol reverses TGF-β1-stimulated type 4 collagen gene transcription in murine mesangial cells. Am J Physiol 1998, 274:F1113-F1118
8. Rosenmann E, Yanko L, Cohen AM: Female sex hormone and nephropathy in Cohen diabetic rat (genetically selected sucrose-fed). Horm Metab Res 1984, 16:11-16
9. Gades MD, Stern JS, Goor HV, Nguyen D, Johnson PR, Kaysen GA: Estrogen accelerates the development of renal disease in female obese Zucker rats. Kidney Int 1998, 53:130-135
10. Tomiyoshi Y, Sakemi T, Aoki S, Miyazono M: Different effects of castration and estrogen administration on glomerular injury in spontaneously hyperglycemic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Nephron 2002, 92:860-867
11. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. J Am Med Assoc 2003, 289:3243-3253
12. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999, 282:637-645
13. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harpar KD, MORE Investigators: Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene) randomized trial. J Am Med Assoc 2002, 287:847-857
14. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000, 85:214-218
15. Neugarten J, Acharya A, Lei J, Silbiger S: Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. Am J Physiol Renal Physiol 2000, 279:F309-F318
16. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCβ inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000, 14:439-447
17. Hugo C, Pichler R, Gordon K, Schmidt R, Amieva M, Couser WG, Furthmayr H, Johnson RJ: The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. J Clin Invest 1996, 97:2499-2508
18. Isono M, Chen S, Hong SW, Cruz MCI, Ziyadeh FN: Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-β-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002, 296:1356-1365
19. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH: Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990, 39:1116-1124
20. Neugarten J, Medve I, Lei J, Silbiger SR: Estradiol suppresses mesangial cell type IV collagen synthesis via activation of the MAP kinase cascade. Am J Physiol 1999, 277:F875-F881
21. Guccione M, Silbiger S, Lei J, Neugarten J: Estradiol upregulates mesangial cell MMP-2 activity via the transcription factor AP-2. Am J Physiol Renal Physiol 2002, 282:F164-F169
22. Potier M, Elliot SJ, Tack I, Lenz O, Striker GE, Striker LJ, Karl M: Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J Am Soc Nephrol 2001, 12:241-251
23. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994, 331:1286-1292
24. Zdunek M, Silbiger S, Lei J, Neugarten J: Protein kinase CK2 mediates TGF-beta1-stimulated type IV collagen gene transcription and its reversal by estradiol. Kidney Int 2001, 60:2097-2108
25. Nielsen CB, Krag S, Osterby R, Flyvbjerg A, Nyengaard J, Forman A, Wogensen L: Transforming growth factor beta1-induced glomerulopathy is prevented by 17beta-estradiol supplementation. Virchows Arch 2004, 444:561-566
26. Ziyadeh FN, Hoffman BB, Man DC, Iglesias-de la Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression and glomerular mesangial matrix expression by treatment with monoclonal anti-TGF-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000, 97:8015-8020
27. Kang D-H, Yu ES, Yoon K-I, Johnson R: The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. Am J Pathol 2004, 164:679-688
28. Shim GL, Kis LL, Warner M, Gustafsson JA: Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc Natl Acad Sci USA 2004, 101:1720-1724
29. Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ: Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am J Pathol 2002, 160:1877-1885
30. Elliot SJ, Karl M, Berho M, Poiter M, Zheng F, Leclercq B, Striker GE, Striker LJ: Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol 2003, 162:1441-1448
31. Lewis JT, Foglia VG, Rodrigues RR: The effects of steroids on the incidence of diabetes in rats after subtotal pancreatectomy. Endocrinology 1950, 46:111-121
32. Gonzalez C, Alonso A, Grueso NA, Diaz F, Esteban MM, Fernandez S, Patterson AM: Role of 17β-estradiol administration on insulin sensitivity in the rat: implications for the insulin receptor. Steroid 2002, 67:993-1005
33. Andersson B, Johannsson G, Holm G, Bengtsson BA, Sashegyi A, Pavo I, Mason T, Anderson PW: Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab 2002, 87:122-128
34. Quo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M: Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004, 53:200-208
35. Peach K, Webb P, Kuiper G, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997, 277:1508-1510
36. Goldfrank D, Haytoglu T, Frishman WH: Raloxifene, a new selective estrogen receptor modulator. J Clin Pharmacol 1999, 39:767-774